These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38279516)

  • 1. Estimating the clinical and budgetary impact of using angiotensin receptor neprilysin inhibitor as first line therapy in patients with HFrEF.
    Bergh N; Lindmark K; Lissdaniels J; Lanne G; Käck O; Cowie MR
    ESC Heart Fail; 2024 Apr; 11(2):1153-1162. PubMed ID: 38279516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction.
    Lee YC; Lin JK; Ko D; Cheng S; Patorno E; Glynn RJ; Tsacogianis T; Kim DH
    J Am Geriatr Soc; 2023 Oct; 71(10):3110-3121. PubMed ID: 37345734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Experience of Angiotensin Receptor-Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease.
    Chang HY; Lin CC; Chao CJ; Lin YC; Wang YC; Liao CT; Huang JL; Lee YH; Huang CY; Chien LN; Hsu CY
    Mayo Clin Proc; 2023 Jan; 98(1):88-99. PubMed ID: 36109207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure.
    Fonarow GC; Hernandez AF; Solomon SD; Yancy CW
    JAMA Cardiol; 2016 Sep; 1(6):714-7. PubMed ID: 27437874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40.
    Zhao M; Xin Y; Li J; Cao X; Liu X
    Medicine (Baltimore); 2019 Sep; 98(39):e17296. PubMed ID: 31574852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term impact of angiotensin receptor-neprilysin inhibitor based on short-term treatment response in heart failure.
    Park HK; Park JS; Kim MS; Lee E; Choi H; Park YJ; Park BE; Kim HN; Kim N; Bae MH; Lee JH; Park HS; Cho Y; Jang SY; Yang DH
    ESC Heart Fail; 2023 Dec; 10(6):3430-3437. PubMed ID: 37705397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Socioeconomic Determinants of Angiotensin Receptor-Neprilysin Inhibitor Prescription at Hospital Discharge in Patients With Heart Failure With Reduced Ejection Fraction.
    Tran JS; Loveland MG; Alamer A; Piña IL; Sweitzer NK
    Circ Heart Fail; 2022 Nov; 15(11):e009395. PubMed ID: 36378759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) among patients with heart failure within a large integrated health system.
    Kim BJ; Huang CW; Chung J; Neyer JR; Liang B; Yu AS; Kwong EK; Park JS; Hung P; Sim JJ
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1173-1179. PubMed ID: 36125061
    [No Abstract]   [Full Text] [Related]  

  • 11. Angiotensin-Neprilysin Inhibition as a Paradigm for All?
    Vaduganathan M; Desai AS
    Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure.
    Luo N; Lippmann SJ; Mentz RJ; Greiner MA; Hammill BG; Hardy NC; Laskey WK; Heidenreich PA; Chang CL; Hernandez AF; Curtis LH; Peterson PN; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2019 Feb; 8(3):e010484. PubMed ID: 30712431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter-2 inhibitors for patients with heart failure with reduced ejection fraction: a meta-analysis.
    Huang Y; Fang C; Zhang Y; Ma L; Zhou H; Ye H
    J Cardiovasc Med (Hagerstown); 2023 Feb; 24(2):123-131. PubMed ID: 36583980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Retrospective Cohort Evaluation of a Pharmacist-Led Approach for Transitioning Patients to an Angiotensin Receptor-Neprilysin Inhibitor.
    Rana K; Jay J; Patel S; Sueta C; Deyo Z
    J Pharm Pract; 2023 Oct; 36(5):1061-1067. PubMed ID: 35392695
    [No Abstract]   [Full Text] [Related]  

  • 15. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
    Khariton Y; Fonarow GC; Arnold SV; Hellkamp A; Nassif ME; Sharma PP; Butler J; Thomas L; Duffy CI; DeVore AD; Albert NM; Patterson JH; Williams FB; McCague K; Spertus JA
    JACC Heart Fail; 2019 Nov; 7(11):933-941. PubMed ID: 31521679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.
    Arfsten H; Goliasch G; Bartko PE; Prausmüller S; Spinka G; Cho A; Novak J; Haslacher H; Strunk G; Struck J; Hülsmann M; Pavo N
    Br J Clin Pharmacol; 2021 Mar; 87(3):916-924. PubMed ID: 32598074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis.
    Jariwala P; Punjani A; Boorugu H; Madhawar DB
    Indian Heart J; 2021; 73(2):211-213. PubMed ID: 33865520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.
    Książczyk M; Lelonek M
    Heart Fail Rev; 2020 May; 25(3):393-402. PubMed ID: 31713710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ARNI in HFrEF-One-Centre Experience in the Era before the 2021 ESC HF Recommendations.
    Niemiec R; Morawska I; Stec M; Kuczmik W; Swinarew AS; Stanula A; Mizia-Stec K
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
    Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
    Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.